NL-OMON23732
Completed
Not Applicable
The REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization
The Sint Maartenskliniek0 sites140 target enrollmentStarted: TBDLast updated:
ConditionsRheumatoid Arthritis
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- The Sint Maartenskliniek
- Enrollment
- 140
Overview
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Rheumatoid arthritis: either 2010 ACR RA and/or 1987 RA criteria and/or clinical diagnosis of the treating rheumatologist, fulfilled at any time point between start of the disease and inclusion.
- •RTX retreatment: at least once RTX in the last 18 months for RA in a dose of 1 × 1000 mg, 2 × 1000 mg or 2 × 500 mg and no other biologicals received after last RTX dose. Patients treated with innovator RTX (MabThera) as well as registered biosimilars will be included.
Exclusion Criteria
- •Patients with known (non\-)response to ultra\-low dose RTX (below 1 × 1000 mg)
- •Current corticosteroid dosing above 10 mg per day prednisolone equivalent
Investigators
Similar Trials
Active, not recruiting
Phase 1
REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritisEUCTR2016-002908-15-NLSint Maartenskliniek140
Unknown
Not Applicable
Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?Rheumatoid ArthritisRemissionNCT02140229Assistance Publique - Hôpitaux de Paris450
Terminated
Phase 2
Lovastatin for the Treatment of Mildly Active Rheumatoid ArthritisRheumatoid ArthritisNCT00302952National Institute of Allergy and Infectious Diseases (NIAID)64
Suspended
Not Applicable
The RAINBOW study: Rheumatoid Arthritis ImplemeNtation of Biological dose Optimization in real WorldRheumatoid Arthritis (RA)NL-OMON22185This is an investigator-initiated study, funded by the Sint Maartenskliniek320
Completed
Not Applicable
BeSt, BehandelStrategieën in Reumatoïde Artritis.NL-OMON24149Dutch College of Health Insurance Companies508